ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Nivolumab

Show all topics

DOI

10.1016/s1470-2045(18)30148-7

Other Formats

PDF